A Phase 3 Study of Abatacept in Chinese Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

Rheumatoid Arthritis (RA) Clinical Trial

Official title:

A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Abatacept 125mg Administered Subcutaneously in Chinese Subjects With Active Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02722694
• Other study ID #: SIM-126-III
• Status: Recruiting
• Phase: Phase 3
• First received: March 10, 2016
• Last updated: September 12, 2016
• Start date: August 2016
• Est. completion date: December 2017

Study information

• Verified date: August 2016
• Source: Jiangsu Simcere Pharmaceutical Co., Ltd.
• Contact: Xiaofeng Zeng
• Phone: 86-10-69158793
• Email: xiaofeng.zeng[@]cstar.org.cn
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to demonstrate superior efficacy of abatacept 125mg administrated SC weekly comparing to placebo after 24 weeks treatment in Chinese subjects who have active rheumatoid arthritis, are receiving methotrexate and experiencing an inadequate response to methotrexate. This will be estimated by the proportion of subjects meeting the American College of Rheumatology (ACR) criteria for 20% improvement (ACR20).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 360
• Est. completion date: December 2017
• Est. primary completion date: June 2017
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects are willing to participate in this study and sign informed consent;

• Subjects must meet the criteria of the America Rheumatism Association (1987) for the diagnosis of rheumatoid arthritis and ACR (1991) functional classes I, II or III;

• Subjects must have had Rheumatoid Arthritis for at least 6 months;

• Subjects who have inadequately response to MTX, must have been taking methotrexate for at least 3 months with minimal dose of 10 mg weekly, and at a stable dose for at least 28 days prior to randomization (Day 1). Methotrexate weekly dose as low as 7.5 mg is permitted for subjects who cannot tolerate higher dose, and the intolerance of higher dose than 7.5mg weekly should be well documented;

• Subjects must have the following disease activity at randomization:

1. 6 or more swollen joints(66 joint count);

2. 8 or more tender joints(68 joint count); and

3. C reactive protein (hsCRP) > 3 mg/L (based on the result of screening visit) or ESR = 28mm/hr;

• All DMARDs (except methotrexate) should be discontinued for at least 28 days prior to study randomization (Day 1), Leflunomide must have been discontinued =8 weeks (the subject can be washed-out with cholestyramine according to label recommendations);

• Oral corticosteroid treatment must have been reduced to the prednisone = 10 mg daily or equivalent for 28 days,and stabilized for at least 25 out of 28 days prior to randomization (Day 1). Corticosteroid administered by intra-articular (IA) or intramuscular (IM) will not be allowed 28 days prior to randomization (Day 1);

• Stable NSAIDs are permitted;

• Male and female subject =18 years old;

• Women of childbearing potential (WOCBP) must have a negative pregnancy test within 24 hours prior to the start of study medication;

Exclusion Criteria:

• WOCBP and male patients of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 10 weeks after the last dose of study medication;

• Women who are pregnant or breast-feeding;

• Women with a positive pregnancy test on enrollment or prior to study drug administration;

• Subjects meet diagnosis criteria of other rheumatoid disease (e.g., systemic lupus erythematosus);

• Subjects with active vasculitis of the major organ systems (except for subcutaneous rheumatoid nodules);

• Current symptoms of severe, progressive or uncontrolled diseases of renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, neurological, or cerebral. Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study;

• Subjects with a history of cancer within the last five years (other than non-melanoma skin cell cancers cured by local resection). Existing non-melanoma skin cell cancers must be removed prior to dosing. Subjects with carcinoma in situ, treated with definitive surgical intervention, are allowed;

• Subjects who have a history of drug or alcohol abuse;

• Subjects with any serious bacterial infection within the last 3 months (such as pneumonia or pyelonephritis, unless treated and resolved with antibiotics);

• Subjects with serious, chronic or recurrent bacterial infection (such as recurrent pneumonia and chronic bronchiectasis);

• Subjects at risk for tuberculosis (TB), Specially, :

1. Having evidences of clinical, imaging or lab test of current active or latent pulmonary tuberculosis;

2. Having active pulmonary tuberculosis during the past 3 years, even if had treated;

3. Having history of active pulmonary tuberculosis more than 3 years ago, unless the appropriate duration and types of anti-tuberculosis drug is well documented;

• Subjects with herpes zoster that resolved less than 2 months before enrollment;

• Subjects with evidence (as assessed by the Investigator) of active or latent bacterial or viral infections at the time of potential enrollment, including subjects with evidence of Human Immunodeficiency Virus (HIV) infection;

• Subjects are impaired, incapacitated, or incapable of completing study related assessment;

• Hepatitis-B surface antigen-positive subjects.

• Hepatitis C antibody-positive subjects

• HIV antibody-positive subjects

• Subjects with any of the following laboratory values:

1. Hgb < 85 g/L

2. white blood cell count < 3,000/mm3(3×10^9/L)

3. Platelets < 100,000/mm3(100×10^9/L);

4. Creatinine clearance < 40 mL/min;

5. Serum glutamic pyruvic transaminase (GPT or ALT) or glutamic oxaloacetic transaminase (GOT or AST)>2 times upper limit of normal;

6. Any other laboratory test results that, in the opinion of the Investigator, might place the subject at unacceptable risk for participation in this study;

• Subjects who have received treatment with rituximab at any time;

• Subjects who had prior exposure to abatacept or CTLA4-Ig;

• Subjects who have received treatment with any investigational drug within 28 days (or less than 5 terminal half-lives of elimination) (whichever is longer);

• Subjects currently (when signing informed consent) treated with an anti-tumor necrosis factor (TNF) therapy, such as adalimumab and infliximab (within 8 weeks of the last dose), or etanercept (within 4 weeks of the last dose);

• Subjects who discontinued an approved biologic RA therapy due to lack of efficacy in the past;

• Subjects exposed to multiple (>3) approved biologic RA therapies in the past;

• Subjects currently treated with anakinra unless a minimum 4-week wash-out period has been completed before Day 1;

• Subjects who received prior treatment with any investigational biologic not currently approved;

• Subjects who had been exposed to any approved biologic within 4 weeks or 5 half-lives, whichever was longer;

• Subjects are (when signing informed consent)receiving an investigational biologic RA therapy or an approved biologic RA therapy;

• Subjects who have received any active vaccine within 3 months of the first dose of the study medication or plan to receive active vaccine during the study;

• Prisoners or subjects who are involuntarily incarcerated;

• Subjects who are compulsorily detained for treatment either a psychiatric or physical (e.g., infectious disease) illness;

• Subjects who are illiterate.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis (RA)

Intervention

Drug:
• Subcutaneous(SC) Abatacept
Subjects received 125mg weekly SC abatacept injections for 24 weeks. All subjects who complete 24 weeks double-blind treatment are eligible to enter open label period. During this period, subjects in placebo group will be switched to receive abatacept 125mg administered SC weekly till week 52. Subjects in abatacept group will continue to receive abatacept 125mg weekly.

Other:
• Placebo
Subjects received weekly SC placebo injections for 24 weeks

Drug:
• Methotrexate
All Subjects received backup Methotrexate treatment.

Locations

Country	Name	City	State
China	Peking union medical college hospital	Beijing	Beijing

Sponsors (2)

Lead Sponsor	Collaborator
Jiangsu Simcere Pharmaceutical Co., Ltd.	Bristol-Myers Squibb

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	The mean change of disease activity score from baseline by measuring DAS28-CRP at 24 weeks (Day 169)	The DAS28 index measures disease activity in rheumatoid arthritis and is a composite derived from the number of swollen/tender joints, laboratory tests of inflammation (C-reactive protein measured in mg/L), and participant assessment of global health (by marking a visual analog scale 100 mm line from "very good" to "very bad"). A higher DAS28 score indicates worse control of disease. High disease activity is > 5.1, low disease activity is < 3.2 and remission is < 2.6.	Day 169	No
Other	The mean change of HAQ-DI from baseline at 24 weeks (Day 169)		Day 169	No
Other	Cmin of abatacept 125 mg administered SC weekly		Day1 to Day196 in double-blind period	No
Other	Cmax of abatacept 125 mg administered SC weekly		Day71 to Day78 in open-label period	No
Other	Area Under Curve (AUC) of abatacept 125 mg administered SC weekly		Day71 to Day78 in open-label period	No
Other	Anti-abatacept antibodies		Day1 to Day421	No
Other	Anti cytotoxic T lymphocyte-associated antigen-4(CTLA-4) antibodies		Day1 to Day421	No
Primary	The proportion of subjects meeting ACR 20 at 24 weeks (Day 169)	The ACR 20 definition of improvement is a 20% improvement from baseline in the number of tender and swollen joints, and a 20% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein).	Day 169	No
Secondary	The proportion of subject meeting Health Assessment Questionnaire Disability Index (HAQ-DI) improvement at 24 weeks (Day 169)	The HAQ questionnaire includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ-DI response=an improvement of at least 0.3 units from baseline in HAQ-DI.	Day 169	No
Secondary	The proportion of subjects meeting ACR 50 at 24 weeks (Day 169)	The ACR 50 definition of improvement is a 50% improvement from baseline in the number of tender and swollen joint counts, and a 50% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein).	Day 169	No
Secondary	The proportion of subjects meeting ACR 70 at 24 weeks (Day 169)	The ACR 70 definition of improvement is a 70% improvement from baseline in the number of tender and swollen joint counts, and a 70% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein).	Day 169	No